title: Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?
abstract: In the context of scarce public resources, patient interest groups have increasingly turned to private organizations for financing, including the pharmaceutical industry. This practice puts advocacy groups in a situation of potential conflicts between the interests of patients and those of the drug companies. The interests of patients and industry can converge on issues related to the approval and reimbursement of medications. But even on this issue, interests do not always align perfectly. Using the Quebec example of Coalition Priorité Cancer (CPC) as a case study, we examine the ethical issues raised by such financial relationships in the context of drug reimbursement decision-making. We collected, compiled and analyzed publicly available information on the CPC's organization and activities; this approach allowed us to raise and discuss important questions regarding the possible influence exerted on patient groups by donors. We conclude with some recommendations.
authors: Doctoral Student, Applied Human Sciences (Bioethics Option), Bioethics Programme, Department of Social and Preventive Medicine, University of Montreal, Montreal, QC.
authors: David
authors: D
authors: Hughes
authors: Bryn
authors: B
authors: Williams-Jones
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D016265:Conflict of Interest / Q000191:economics; D016527:Drug Costs / Q000941:ethics; D004345:Drug Industry / Q000191:economics / Q000941:ethics* / Q000458:organization & administration; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics / Q000941:ethics*; D009369:Neoplasms / Q000188:drug therapy*; D010344:Patient Advocacy / Q000191:economics / Q000941:ethics*; D011792:Quebec
chemical_list: D000970:Antineoplastic Agents
references: BMJ. 2006 May 27;332(7552):1268-71
references: 16735342
references: Soc Sci Med. 2010 Apr;70(8):1171-5
references: 20163903
references: BMJ. 2007 May 5;334(7600):935
references: 17478846
references: Aust Health Rev. 2004 Nov 8;28(2):228-37
references: 15527403
references: Sociol Health Illn. 2004 Sep;26(6):737-56
references: 15383039
references: Int J Health Serv. 2007;37(4):711-33
references: 18072317
references: Am J Public Health. 2011 Apr;101(4):602-9
references: 21233424
references: Health Aff (Millwood). 2004 Jan-Feb;23(1):52-63
references: 15002628
references: Sociol Health Illn. 2008 Sep;30(6):929-43
references: 18761512
references: EMBO Rep. 2008 Feb;9(2):119-23
references: 18246102
references: BMC Public Health. 2006 Aug 03;6:201
references: 16887025
references: Int J Occup Environ Health. 2005 Oct-Dec;11(4):349-55
references: 16350468
references: BMJ. 2003 May 31;326(7400):1208-10
references: 12775627